Corteva Agriscience

Corteva Agriscience is placed second in this category on the strength of a seed franchise that supplied US$9.9 billion of its US$17.4 billion in 2025 net sales, backed by the Pioneer brand and direct technical control over 68% of the global seed production area for its crops. It scores level with Bayer Crop Science at 89 but is ordered behind it because the seed revenue base is smaller and because the company is mid-surgery: the October 2025 decision to separate seeds and genetics into a listed business called Vylor adds execution risk that a division still inside its parent does not carry. The score records scale plus transition.

Industry Position

Corteva is the most seed-concentrated of the large row-crop manufacturers profiled here. Its seeds segment generated US$9.9 billion of the US$17.4 billion in 2025 net sales, with operating EBITDA of US$2.64 billion, and the genetics franchise reaches growers through Pioneer, Brevant and the Enlist E3 and Conkesta E3 trait brands. The rest of revenue comes from crop protection chemistry, which is the piece scheduled to stay inside the Corteva legal entity after the 2026 separation.

Its position rests on control rather than breadth. Corteva directly controls and technically guides 68% of the global seed production area for its crops - unusual in an industry where multiplication is normally contracted to independent growers - and it operates in approximately 110 countries with about 120 research and breeding facilities. Unlike Bayer Crop Science and BASF Agricultural Solutions, it is nobody's division: a 2019 spin-off from the DowDuPont merger, it carries no parent and files its own accounts, so US$17.4 billion of net sales is the whole corporate footprint.

Competitive Advantages

The first advantage is the Pioneer franchise and the trait stack attached to it. Pioneer hybrid corn and soybeans date to 1926 and sell into roughly 110 countries, while Enlist E3 carries weed-control tolerance and Conkesta E3 insect protection inside the same seed. Selling genetics and traits as one unit is what produced organic sales growth of 5% in 2025 and share gains in both North America and Brazil.

The second is research cadence. More than 2,500 new seed and crop protection products have been launched since 2019 against US$8.9 billion of cumulative research and development spending, a rate of renewal that keeps Pioneer-branded varieties turning over in a market where a hybrid's commercial life is measured in a handful of seasons. Lumisena, a seed treatment sold alongside the genetics, shows how the company attaches chemistry to the seed instead of selling it separately.

Strategic Expansion

The defining expansion move is subtraction. Corteva's board approved a separation in October 2025 that will divide the company on 1 October 2026: seeds and genetics leave as a standalone listed seed company named Vylor, keeping the Pioneer brand, while crop protection continues under the Corteva name. Both halves gain capital-allocation freedom, and both lose the internal cross-subsidy that a combined seed-and-chemistry portfolio provides.

Alongside the split, Corteva is licensing and buying technology rather than building it alone. It paid US$200 million upfront to FMC under a commercial licensing agreement covering rimisoxafen, and it acquired non-GMO resistant starch durum wheat trait patents from Arcadia Biosciences, a targeted addition to a wheat programme that has been a minor part of the portfolio. In 2025 it also bought back about US$1 billion of its own shares.

Risks & Outlook

The first risk is Latin America, where declining Argentine corn acreage and a weaker Brazilian real pulled overseas revenue down in 2025 even where volumes held. That is a double squeeze - fewer hectares, and less revenue per hectare once converted - and it lands hardest on a seed business that has been gaining share in Brazil.

The second is the Vylor spin-off itself. Separating roughly 120 breeding and research facilities, shared trait platforms and one dealer network into two listed companies within a year of board approval is a demanding operational programme, and the seed entity will carry the seasonal working-capital profile of genetics alone. If the split slips, or if the two entities underinvest in the pipeline they still share, the share gains of 2025 would mark the top of a cycle rather than its base. VerityRank Score of 89/100.